Valganciclovir to Reduce T Cell Activation in HIV Infection
|2||Active, not recruiting||
Rifaximin for Chronic Immune Activation in People With HIV
Analysis of Immune Responses to HIV Vaccines
† Study has passed its completion date and status has not been verified in more than two years.